The role of Rebamipide ophthalmic suspension in management of dry eye disease

References

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007;5:75–92.
2. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Dry Eye Syndrome. Limited revision. San Francisco, CA: American Academy of Ophthalmology; 2011. Available at: http://one.aao.org/CE/PracticeGuidelines/PPP.aspx. Accessed July 26, 2012.
3. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol 2009;3:405–12.
4. Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol 2010;21:310–6.
5. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea 2004;23(8):751–761.
6. Wolff, E.: Mucocutaneous junction of lid margin and the distribution of the tear fluid.trans.ophthal.Soc.U.k.66:291- 308,1946.
7. Holly, F.J. and Lemp, M, A.: Tear Physiology And dry Eyes.Surv.Ophthalmol.22:69-87,1977.
8. Tear film- Lemp MA. Tear film: new concepts and implications for the management of the dry eye. Trans New Orleans Acad Ophthalmol. 1987;35:53–64.
9. Asbell PA. Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion. Curr Med Res Opin 2006;22:2149 –57.
10. Luo, D.-Q. Li, A. Doshi, W. Farley, R. M. Corrales, and S.C. Pflugfelder, “Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signalling pathways on the ocular surface,” Investigative Ophthalmology & Visual Science, vol. 45, no. 12, pp. 4293–4301, 2004.
11. Shimmura S, Ono M, Shinozaki K, et al. Sodium hyaluronate eye drops in the treatment of dry eyes. Br J Ophthalmol 1995; 79:1007–11.
12. Condon PI, McEwen CG, Wright M, et al. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol. 1999;83:1121–1124.
13. Slusser TG, Lowther GE. Effects of lacrimal drainage occlusion with non-dissolvable intracanalicular plugs on hydrogel contact lens wear. Optom Vis Sci 1998;75:330–8.
14. Sall K, Stevenson OD, Mundorf TK, Reis BL, CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000;107: 631–9.
15. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res. 2001;22:8–18.
16. Baudouin C, Labbe A, Liang H, et al. Preservatives in eye drops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312–34.35.
17. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc U K 1985;104(4):402–409.
18. Arakawa T, Kobayashi K, Yoshikawa T, et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S–13S.
19. Y. Naito and T. Yoshikawa, “Rebamipide: a gastrointestinal protective drug with pleiotropic activities,” Expert Review of Gastroenterology and Hepatology, vol. 4, no. 3,pp. 261– 270, 2010.
20. K. Yamasaki, T. Kanbe, T. Chijiwa, H. Ishiyama, and S. Morita, “Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat,” European Journal of Pharmacology, vol.142, no. 1, pp. 23–29, 1987.
21. Takeji Y, Urashima H, Aoki A, et al. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J OculPharmacol Ther. 2012;28:259–263.
22. Danjo Y, Watanabe H, Tisdale AS, George M, Tsumura T, Abelson MB, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci. 1998;39:2602–9.
23. Rios JD, Shatos M, Urashima H, Tran H, Dartt DA. OPC- 12759 increases proliferation of cultured rat conjunctival goblet cells. Cornea. 2006;25:573–81.
24. Itoh S, Itoh K, Shinohara H. Regulation of Human Corneal Epithelial Mucins by Rebamipide. Curr Eye Res. 2013;39:133–41.
25. Ueta M, Sotozono C, Yokoi N, Kinoshita S. Rebamipide suppresses Poly I: C stimulated Cytokine production in human conjunctival epithelial cells. J Ocul Pharmacol Ther. 2013;29:688–93.
26. H. Tanaka, K. Fukuda, W. Ishida, Y. Harada, T. Sumi, and A. Fukushima, “Rebamipide increases barrier function and attenuates TNF������-induced barrier disruption and cytokine expression in human corneal epithelial cells,” The British Journal of Ophthalmology, vol. 97, no. 7, pp. 912–916,
27. Kinoshita S, Awamura S, Nakamichi N, Suzuki H, Oshiden K, Yokoi N. Rebamipide Ophthalmic Suspension Long-term Study Group. A Multicenter, Open-Label, 52-Week Study of 2% Rebamipide (OPC-12759) Ophthalmic Suspension in Patients with Dry Eye. Am J Ophthalmol. 2014;157:576–83.
28. Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N. Rebamipide Ophthalmic Suspension Phase 3 Study Group. Ophthalmology. 2013;120:1158–65.
29. Kaori Ueda, Wataru Matsumiya*, Keiko Otsuka, Yoshifumi Maeda, Takayuki Nagai and Makoto Nakamura, “effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye”, BMC Ophthalmology (2015) 15:58 DOI 10.1186/s12886-015-
    [Google Scholar] 0040-0.
30. A. Arimoto, K. Kitagawa, N. Mita, Y. Takahashi, E. Shibuya, and H. Sasaki, “Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sj¨ogren syndrome patients with or without punctal occlusions,” Cornea, vol. 33, no. 8, pp. 806–811, 2014.
31. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci. 2002;43:1004–11.
32. Koh S, Inoue Y, Sugmimoto T, Maeda N, Nishida K. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32:1219–23. Laxmi Dorennavar et al. The role of Rebamipide Ophthalmic suspension in Management of Dry…. Indian Journal of Clinical and Experimental Ophthalmology, October – December 2015;1(4):191-196 196
33. J. M. Herreras, J. C. Pastor, M. Calonge, and V. M. Asensio, “Ocular surface alteration after long-term treatment with an anti-glaucomatous drug,” Ophthalmology, vol. 99, no. 7, pp. 1082–1088, 1992.
34. E. W. Leung, F. A. Medeiros, and R. N. Weinreb, “Prevalence of ocular surface disease in glaucoma patients,” Journal of Glaucoma, vol. 17, no. 5, pp. 350–355, 2008.
35. R. D. Fechtner, D. G. Godfrey, D. Budenz, J. A. Stewart, W. C. Stewart, and M. C. Jasek, “Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications,” Cornea, vol. 29, no. 6, pp. 618–621, 2010.
36. A. Niiya, N. Yokoi, Y. Matsumoto et al., “Effect of beta- blocker eye drops on corneal epithelial barrier function,” Ophthalmologica, vol. 214, no. 5, pp. 332–336, 2000.
37. Naoto Tokuda, Yasushi Kitaoka, Akiko Matsuzawa, Junsuke Miyamoto, Shinsuke Sakae, Yasunari Munemasa, and Hitoshi Takagi, “The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patient”, Hindawi Publishing Corporation Journal of Ophthalmology Volume 2015, Article ID 689076,
38. Mayumi Ueta, Chie Sotozono, Ayaka Koga, Norihiko Yokoi and Shigeru Kinoshita, “Usefulness of a New Therapy Using Rebamipide Eye drops in Patients with VKC/AKC Refractory to Conventional Anti-Allergic Treatments”, Allergology International.vol63 2014;63:75-81.